Selected research
Industry Growth & Trends
Global Lung Cancer Screening Software Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Lung Cancer Screening Software market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Lung Cancer Screening Software is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Lung Cancer Screening Software is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Lung Cancer Screening Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Lung Cancer Screening Software market include Siemens Healthineers, GE HealthCare, Philips Healthcare, Canon Medical Systems, United Imaging Healthcare, InferVision, Airdoc, VUNO and Lunit, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Lung Cancer Screening Software market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Lung Cancer Screening Software market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Lung Cancer Screening Software market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Lung Cancer Screening Software.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Lung Cancer Screening Software market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Lung Cancer Screening Software Market by Company
Siemens Healthineers
GE HealthCare
Philips Healthcare
Canon Medical Systems
United Imaging Healthcare
InferVision
Airdoc
VUNO
Lunit
Qure.ai
Riverain Technologies
Zebra Medical Vision
Arterys
Deepwise
EverFortune AI
Lung Cancer Screening Software Segment by Type
Cloud-Based
Web-Based
Lung Cancer Screening Software Segment by Application
Hospitals
Medical Examination Institutions
Public Health Screening
Others
Lung Cancer Screening Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Screening Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Screening Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Screening Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Lung Cancer Screening Software companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Cloud-Based
- Web-Based
Applications
- Hospitals
- Medical Examination Institutions
- Public Health Screening
- Others
Companies covered
- Siemens Healthineers
- GE HealthCare
- Philips Healthcare
- Canon Medical Systems
- United Imaging Healthcare
- InferVision
- Airdoc
- VUNO
- Lunit
- Qure.ai
- Riverain Technologies
- Zebra Medical Vision
- Arterys
- Deepwise
- EverFortune AI
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Lung Cancer Screening Software Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Lung Cancer Screening Software Market Size by Region (2021-2032)
- 1.4.1 Global Lung Cancer Screening Software Market Size by Region (2021-2026)
- 1.4.2 Global Lung Cancer Screening Software Market Size by Region (2027-2032)
- 1.5 Key Regions Lung Cancer Screening Software Market Size (2021-2032)
- 1.5.1 North America Lung Cancer Screening Software Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Lung Cancer Screening Software Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Lung Cancer Screening Software Market Size Growth Rate (2021-2032)
- 1.5.4 South America Lung Cancer Screening Software Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Lung Cancer Screening Software Market Size Growth Rate (2021-2032)
2 Lung Cancer Screening Software Market by Type
- 2.1 Type Introduction
- 2.1.1 Cloud-Based
- 2.1.2 Web-Based
- 2.2 Global Lung Cancer Screening Software Market Size by Type
- 2.2.1 Global Lung Cancer Screening Software Market Size Overview by Type (2021-2032)
- 2.2.2 Global Lung Cancer Screening Software Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Lung Cancer Screening Software Market Size Forecasted by Type (2027-2032)
- 2.3 Global Lung Cancer Screening Software Market Size by Regions
- 2.3.1 North America Lung Cancer Screening Software Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Lung Cancer Screening Software Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Lung Cancer Screening Software Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Lung Cancer Screening Software Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Lung Cancer Screening Software Market Size Breakdown by Type (2021-2026)
3 Lung Cancer Screening Software Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospitals
- 3.1.2 Medical Examination Institutions
- 3.1.3 Public Health Screening
- 3.1.4 Others
- 3.2 Global Lung Cancer Screening Software Market Size by Application
- 3.2.1 Global Lung Cancer Screening Software Market Size Overview by Application (2021-2032)
- 3.2.2 Global Lung Cancer Screening Software Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Lung Cancer Screening Software Market Size Forecasted by Application (2027-2032)
- 3.3 Global Lung Cancer Screening Software Market Size by Regions
- 3.3.1 North America Lung Cancer Screening Software Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Lung Cancer Screening Software Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Lung Cancer Screening Software Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Lung Cancer Screening Software Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Lung Cancer Screening Software Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Lung Cancer Screening Software Industry Trends
- 4.2 Lung Cancer Screening Software Industry Drivers
- 4.3 Lung Cancer Screening Software Industry Opportunities and Challenges
- 4.4 Lung Cancer Screening Software Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Lung Cancer Screening Software Revenue (2021-2026)
- 5.2 Global Lung Cancer Screening Software Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Lung Cancer Screening Software Key Company Headquarters & Area Served
- 5.4 Global Lung Cancer Screening Software Company, Product Type & Application
- 5.5 Global Lung Cancer Screening Software Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Lung Cancer Screening Software Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Lung Cancer Screening Software Players Market Share by Revenue in 2025
- 5.6.3 2025 Lung Cancer Screening Software Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Siemens Healthineers
- 6.1.1 Siemens Healthineers Company Information
- 6.1.2 Siemens Healthineers Business Overview
- 6.1.3 Siemens Healthineers Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Siemens Healthineers Lung Cancer Screening Software Product Portfolio
- 6.1.5 Siemens Healthineers Recent Developments
- 6.2 GE HealthCare
- 6.2.1 GE HealthCare Company Information
- 6.2.2 GE HealthCare Business Overview
- 6.2.3 GE HealthCare Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 GE HealthCare Lung Cancer Screening Software Product Portfolio
- 6.2.5 GE HealthCare Recent Developments
- 6.3 Philips Healthcare
- 6.3.1 Philips Healthcare Company Information
- 6.3.2 Philips Healthcare Business Overview
- 6.3.3 Philips Healthcare Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Philips Healthcare Lung Cancer Screening Software Product Portfolio
- 6.3.5 Philips Healthcare Recent Developments
- 6.4 Canon Medical Systems
- 6.4.1 Canon Medical Systems Company Information
- 6.4.2 Canon Medical Systems Business Overview
- 6.4.3 Canon Medical Systems Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Canon Medical Systems Lung Cancer Screening Software Product Portfolio
- 6.4.5 Canon Medical Systems Recent Developments
- 6.5 United Imaging Healthcare
- 6.5.1 United Imaging Healthcare Company Information
- 6.5.2 United Imaging Healthcare Business Overview
- 6.5.3 United Imaging Healthcare Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 United Imaging Healthcare Lung Cancer Screening Software Product Portfolio
- 6.5.5 United Imaging Healthcare Recent Developments
- 6.6 InferVision
- 6.6.1 InferVision Company Information
- 6.6.2 InferVision Business Overview
- 6.6.3 InferVision Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 InferVision Lung Cancer Screening Software Product Portfolio
- 6.6.5 InferVision Recent Developments
- 6.7 Airdoc
- 6.7.1 Airdoc Company Information
- 6.7.2 Airdoc Business Overview
- 6.7.3 Airdoc Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Airdoc Lung Cancer Screening Software Product Portfolio
- 6.7.5 Airdoc Recent Developments
- 6.8 VUNO
- 6.8.1 VUNO Company Information
- 6.8.2 VUNO Business Overview
- 6.8.3 VUNO Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 VUNO Lung Cancer Screening Software Product Portfolio
- 6.8.5 VUNO Recent Developments
- 6.9 Lunit
- 6.9.1 Lunit Company Information
- 6.9.2 Lunit Business Overview
- 6.9.3 Lunit Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Lunit Lung Cancer Screening Software Product Portfolio
- 6.9.5 Lunit Recent Developments
- 6.10 Qure.ai
- 6.10.1 Qure.ai Company Information
- 6.10.2 Qure.ai Business Overview
- 6.10.3 Qure.ai Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Qure.ai Lung Cancer Screening Software Product Portfolio
- 6.10.5 Qure.ai Recent Developments
- 6.11 Riverain Technologies
- 6.11.1 Riverain Technologies Company Information
- 6.11.2 Riverain Technologies Business Overview
- 6.11.3 Riverain Technologies Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Riverain Technologies Lung Cancer Screening Software Product Portfolio
- 6.11.5 Riverain Technologies Recent Developments
- 6.12 Zebra Medical Vision
- 6.12.1 Zebra Medical Vision Company Information
- 6.12.2 Zebra Medical Vision Business Overview
- 6.12.3 Zebra Medical Vision Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Zebra Medical Vision Lung Cancer Screening Software Product Portfolio
- 6.12.5 Zebra Medical Vision Recent Developments
- 6.13 Arterys
- 6.13.1 Arterys Company Information
- 6.13.2 Arterys Business Overview
- 6.13.3 Arterys Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Arterys Lung Cancer Screening Software Product Portfolio
- 6.13.5 Arterys Recent Developments
- 6.14 Deepwise
- 6.14.1 Deepwise Company Information
- 6.14.2 Deepwise Business Overview
- 6.14.3 Deepwise Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Deepwise Lung Cancer Screening Software Product Portfolio
- 6.14.5 Deepwise Recent Developments
- 6.15 EverFortune AI
- 6.15.1 EverFortune AI Company Information
- 6.15.2 EverFortune AI Business Overview
- 6.15.3 EverFortune AI Lung Cancer Screening Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 EverFortune AI Lung Cancer Screening Software Product Portfolio
- 6.15.5 EverFortune AI Recent Developments
7 North America
- 7.1 North America Lung Cancer Screening Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Lung Cancer Screening Software Market Size by Country (2021-2026)
- 7.3 North America Lung Cancer Screening Software Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Lung Cancer Screening Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Lung Cancer Screening Software Market Size by Country (2021-2026)
- 8.3 Europe Lung Cancer Screening Software Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Lung Cancer Screening Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Lung Cancer Screening Software Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Lung Cancer Screening Software Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Lung Cancer Screening Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Lung Cancer Screening Software Market Size by Country (2021-2026)
- 10.3 South America Lung Cancer Screening Software Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Lung Cancer Screening Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Lung Cancer Screening Software Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Lung Cancer Screening Software Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst